PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA(R) in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck

Source :: GlobeNewswire. November 9, 2020
Publication Year :: 2020
Abstract: FLORHAM PARK, N.J., Nov 09, 2020 (GLOBE NEWSWIRE via COMTEX) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing novel cancer therapies and infectious disease vaccines based on [...]

Subjects :: Merck & Company Inc. -- Product development -- Forecasts and trends -- Planning
Clinical trials -- Forecasts and trends
Cancer treatment -- Forecasts and trends
Vaccines -- Product development -- Planning
Biotechnology -- Forecasts and trends
Pembrolizumab -- Forecasts and trends
Biological products industry -- Product development -- Forecasts and trends -- Planning
Head and neck cancer -- Forecasts and trends
T cells -- Forecasts and trends
Company business planning
Market trend/market analysis
Banking, finance and accounting industries
Business
Keytruda (Medication) -- Product development

Tools